12:56 PM EDT, 07/23/2024 (MT Newswires) -- GSK (GSK) said Tuesday that its ViiV Healthcare subsidiary's phase 4 clinical trial showed that the two-drug regimen Dovato has "non-inferior efficacy" compared with the three-drug regimen Biktarvy in people living with human immunodeficiency virus-1, or HIV-1.

The study compared Dovato, or dolutegravir and lamivudine, with the Biktarvy regimen, or bictegravir/emtricitabine/tenofovir alafenamide fumarate, as HIV-1 treatment for people who are virologically suppressed and who could benefit from treatment optimization, the company said.

The study met its primary endpoint, with Dovato showing "non-inferior efficacy" in maintaining viral suppression compared with switching to Gilead Sciences' ( GILD ) Biktarvy at 48 weeks, the company added.

The study also showed in a secondary endpoint that "weight increased significantly" in patients who switched to Biktarvy than in those who took Dovato, according to GSK.

ViiV, which GSK owns with partners Pfizer ( PFE ) and Shionogi, is expected to present the results of its phase 4 study at an international conference Thursday.

Price: 38.91, Change: -0.48, Percent Change: -1.22